Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).
Frank S, Busse P, Rosenthal D, Hernandez M, Swanson D, Garden A, Sturgis E, Ferrarotto R, Gunn G, Patel S, LEE N, Lin A, Snider J, McDonald M, Henson C, Bajaj G, Kalman N, Parvathaneni U, Katz S, Foote R. Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC). Journal Of Clinical Oncology 2024, 42: 6006-6006. DOI: 10.1200/jco.2024.42.16_suppl.6006.Peer-Reviewed Original ResearchProgression-free survivalProgression-free survival HROverall survivalOropharyngeal carcinomaInduction chemotherapyChemoradiation therapyGastrostomy-tube dependenceHazard ratioRate of progression-free survivalManagement of head and neck tumorsIntensity-modulated photon therapyReceipt of induction chemotherapyTreated with chemoradiation therapyIntensity-modulated proton therapySurgical lymph node dissectionHead and neck tumorsPhase III randomized trialWeight loss <5%Bilateral neck treatmentHuman papillomavirus statusLymph node dissectionTarget tumor volumeMedian follow-upDe-intensification strategiesIntent-to-treatSurrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx
Gharzai L, Morris E, Nguyen-Tan P, Rosenthal D, Gillison M, Harari P, Garden A, Zanotti K, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate Endpoints in p16-Positive Squamous Cell Carcinoma of the Oropharynx. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e14. DOI: 10.1016/j.ijrobp.2024.01.035.Peer-Reviewed Original ResearchLocoregional progression-free survivalProgression-free survivalP16-positive oropharyngeal cancerOverall survivalOropharyngeal cancerIncreasing incidence of HPV-related cancersIncidence of HPV-related cancersP16-positive squamous cell carcinomaOptimal treatment paradigmMedian follow-upHPV-related cancersSquamous cell carcinomaMulticenter randomized trialClinical trial endpointsLocoregional progressionDistant metastasisLocal progressionCell carcinomaDefinitive treatmentTreatment paradigmDMFSFollow-upRandomized trialsIncreased incidenceTreatment effectsSurrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis
Gharzai L, Morris E, Suresh K, Nguyen-Tân P, Rosenthal D, Gillison M, Harari P, Garden A, Koyfman S, Caudell J, Jones C, Mitchell D, Krempl G, Ridge J, Gensheimer M, Bonner J, Filion E, Dunlap N, Stokes W, Le Q, Torres-Saavedra P, Mierzwa M, Schipper M. Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis. The Lancet Oncology 2024, 25: 366-375. PMID: 38423050, PMCID: PMC10962533, DOI: 10.1016/s1470-2045(24)00016-0.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalProgression-free survivalIntermediate clinical endpointsMetastasis-free survivalOverall survivalClinical endpointsOropharyngeal cancerComposite endpointIncidence of human papillomavirus (HPV)-related cancersP16-positive squamous cell carcinomaHuman papillomavirus (HPV)-related cancersP16-positive oropharyngeal cancerCancer treated with chemotherapyIndividual patient data meta-analysisMedian follow-upPatient data meta-analysisSquamous-cell carcinomaSquamous cell carcinomaPatient levelClinical trial endpointsTreatment effectsData meta-analysisLocoregional progressionNational Cancer InstituteDistant metastasis